Digital Task Cuts Alzheimer's Trial Screening Time to Two Minutes

Developed by Cumulus Neuroscience, the Symbol Swap task functions as an executive function test that replaces lengthy clinical assessments requiring 10 to 45 minutes of professional time. According to interim results from three independent trials, including the global BioHermes-002 study, the tool accurately differentiates between healthy controls, individuals with mild cognitive impairment, and those with Alzheimer's dementia. Its ability to detect blood-biomarker-defined pathology—specifically pTau-217—even in asymptomatic participants positions it as a high-speed filter for clinical trial enrollment.

By serving as a first-line screen, the platform aims to reduce the high screen-failure rates that plague current drug development. Brian Murphy, Cumulus co-founder and CSO, noted that the task captures signs of underlying pathology that standard tests often miss. Beyond initial screening, data from the CNS-101 study, led by Professor James Rowe of the University of Cambridge, demonstrated that the broader NeuLogiq platform’s cognitive and EEG assessments are well tolerated by patients. These multi-domain digital endpoints offer a pathway to leaner trial designs, allowing researchers to gather sensitive data while reducing the logistical burden on both clinical sites and participants.